Voyager Therapeutics Inc
VYGR
Get informed when a big investor buys or sells
+ FollowMarket Cap$191.54M
Close$
$-3.37
208.6% downside
Current Fair Value
208.6% downsideOvervalued by 208.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $191.54 Million |
|---|---|
| Enterprise Value | $183.18 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.04 |
| Beta | 1.27 |
| Outstanding Shares | 59,496,329 |
Return
| Return on Equity | -67.16% |
|---|---|
| Return on Assets | -53.18% |
| Return on Invested Capital | -48.13% |
Valuation & Multiples
| P/E Ratio | -1.6 |
|---|---|
| PEG | 16.1 |
| Price to Sales | - |
| Price to Book Ratio | 1.55 |
| Enterprise Value to Revenue | 5.02 |
| Enterprise Value to EBIT | -1.89 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
$7.11 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
$4.56 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2795▲ 15.87% |
|---|---|
| Total Calls | 174,979▲ 36.28% |
| Total Puts | 48,900▲ 215.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 56.34%▼ 1.05% |
|---|---|
| Total Invested | $129.40M▼ 2.44% |
| Investors Holding | 139▲ 11.00% |
ESG Score
No data
About Voyager Therapeutics Inc
CEO: G. Andre Turenne